Bensen Daniel

COO Bensen Daniel sells 125,589 shares over two days for $2.0M at $16.17 avg, reducing stake 42.3%; TYRA unprofitable with -$29.9M net income

Bensen Daniel, Chief Operating Officer, executed 2 separate sales totaling 125,589 shares for $2,030,923.43, reducing his holdings from 296,570 shares to 170,981 shares (a 42.3% reduction in stake). The transactions occurred on 2025-11-18 and 2025-11-19 at a blended average price of $16.17, within 0.7% of the 52-week high of $16.73. At the same ticker, Daniel has made 5 prior trades, all sales, concentrated in November 2025 (four recent sales with outcomes not yet measurable). His cross-ticker track record shows a 90-day well-timed rate of 57.14% across 11 prior sells, but his single prior measurable sale at TYRA (2024-02-06) resulted in a positive 90-day return of +1.4%, indicating the stock rose after that sale. The company remains unprofitable with net income of -$29,868,000.00 over its most recent full fiscal year, creating a gap between the stock's recent momentum (30-day: +10.6%, 90-day: +42.0%) and fundamental financial performance.

COO Bensen Daniel sold 131,411 shares at $16.04 blended average for $2.1M, reducing holdings 30.7%

Bensen Daniel, Chief Operating Officer of Tyra Biosciences, executed 4 separate sales totaling 131,411 shares for $2,108,066.97 over a 5-day window (Nov 13-17, 2025), reducing his stake by 30.7% to 296,570 shares. The sales occurred at prices ($16.00–$17.07) near the 52-week high of $16.73, and the stock has rallied 9.7% over the past 30 days and 55.9% over 90 days before this transaction. Across his prior 5 trades at TYRA, Bensen's timing has been mixed: 2 of 5 prior sells subsequently declined beyond 90 days, while 3 produced gains, suggesting no consistent pattern of foresight at this ticker. The company is unprofitable (net income $-29,868,000.00 for its most recent full fiscal year), and the liquidation's scale and timing relative to recent strong price performance warrants attention to whether material developments are expected.